HSP90AB1 Monoclonal Antibody is a highly specific reagent designed to detect and study the heat shock protein 90 alpha family class B member 1 (HSP90AB1), a molecular chaperone critical for protein folding, stability, and cellular stress responses. This antibody is widely used in research to investigate HSP90AB1’s role in cancer, viral infections, and cellular homeostasis. Below is a detailed analysis of its characteristics, applications, and research findings.
Multiple clones targeting HSP90AB1 have been developed, each with distinct properties:
Note: Rabbit polyclonal antibodies (e.g., Proteintech) offer broader species reactivity compared to mouse monoclonals .
HSP90AB1 antibodies are extensively used to detect protein expression levels in lysates. For example:
Clone 5G4: Detects HSP90AB1 in Jurkat, HeLa, HEK293, and NIH/3T3 cells .
Proteintech (11405-1-AP): Validated in 35 publications for WB, with observed bands at 83–90 kDa .
Used to localize HSP90AB1 in tissue sections. Clone 5G4 successfully stains human kidney cancer and brain tissues .
Reveals subcellular localization. Clone 5G4 highlights HSP90AB1 in the cytoplasm of HeLa cells .
Proximity Ligation Assay (PLA) with anti-HSP90AB1 and anti-NFKB1 antibodies detects interactions in HeLa cells, confirming HSP90AB1’s role in nuclear factor κB (NF-κB) signaling .
HSP90AB1 is critical for viral replication:
TGEV (Transmissible Gastroenteritis Coronavirus): HSP90AB1 knockdown reduces viral replication by ~42% in mRNA levels and ~1 log TCID50 in titers .
SARS-CoV-2: HSP90 inhibitors (e.g., VER-82576) block infection by disrupting HSP90AB1-RNA interactions .
Chemoresistance: HSP90AB1 overexpression confers resistance to cisplatin in ovarian cancer by stabilizing IGF1R .
Leukemia: HSP90AB1 inhibition synergizes with CDK7 inhibitors to overcome BCR-ABL1-mediated resistance in chronic myeloid leukemia .
HSP90 Isoforms: HSP90AB1 (but not HSP90AA1) is essential for TGEV infection, highlighting isoform-specific roles .
Proinflammatory Cytokines: HSP90AB1 knockdown reduces TGEV-induced IL-6, TNF-α, and CXCL10/CXCL11 expression .
HSP90AB1 and HSP90AA1 have distinct biological roles. Antibodies must avoid cross-reactivity (e.g., KW-2478 targets HSP90AA1 but not AB1) .
Resistance Mechanisms: Prolonged HSP90 inhibitor use (e.g., PU-H71) can induce HSP90AB1 overexpression or mutations, reducing therapeutic efficacy .